Long-term Follow-up in Patients Affected With Acrofacial Vitiligo

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2011 by Irmandade da Santa Casa de Misericordia de Curitiba.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
Caio Cesar Silva de Castro, Irmandade da Santa Casa de Misericordia de Curitiba
ClinicalTrials.gov Identifier:
NCT01459055
First received: October 21, 2011
Last updated: February 28, 2012
Last verified: October 2011
  Purpose

Acrofacial vitiligo is a clinical form of vitiligo characterized by macules in distal digits, periorificial-facial and ano-genital areas. Vitiligo European Task Force classifies vitiligo as generalized or localized; generalized vitiligo may be further sub-divided into acrofacial, vulgaris and universalis, and localized vitiligo, into segmental and focal. Some authors do not believe that acrofacial is a real vitiligo clinical form, considering it as an initial form of vulgaris vitiligo. The aim of this study is to follow early- diagnosed acrofacial patients during ten years in order to define if these patients will maintain this clinical form or will evolute to a more severe clinical form.


Condition
Vitiligo

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Long-term Ten Years Follow-up in Patients Affected With Acrofacial Vitiligo

Resource links provided by NLM:


Further study details as provided by Irmandade da Santa Casa de Misericordia de Curitiba:

Estimated Enrollment: 100
Study Start Date: August 2010
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients of both genders affected by acrofacial vitiligo diagnosed by one single dermatologist.

Criteria

Inclusion Criteria:

  1. Patients of both genders, aged older than years, able to understand and provide written informed consent and able to allow compliance at the treatment and the requirements of the protocol;
  2. Presence of acrofacial vitiligo;
  3. Able to comprehend and willing to provide written informed consent in accordance with institutional and regulatory guidelines.

Exclusion Criteria:

1- Subjects assessed as not suitable for the study in the opinion of the investigator

2 -Inability to complete survey

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01459055

Contacts
Contact: Caio Cesar C Castro, MD, PhD 00554135682036 caio.castro@pucpr.br

Locations
Brazil
Irmandade da Santa Casa de Misericórdia de Curitiba Recruiting
Curitiba, Parana, Brazil, 80730000
Contact: Caio Cesar Silva de Castro, MD, PhD    00554135682036    caio.castro@pucpr.br   
Principal Investigator: Caio C Silva de Castro, MD, PhD         
Sponsors and Collaborators
Irmandade da Santa Casa de Misericordia de Curitiba
Investigators
Principal Investigator: Caio C Silva de Castro, MD, PhD Irmandade da Santa Casa de Misericórdia de Curitiba
  More Information

No publications provided

Responsible Party: Caio Cesar Silva de Castro, MD, PhD, Irmandade da Santa Casa de Misericordia de Curitiba
ClinicalTrials.gov Identifier: NCT01459055     History of Changes
Other Study ID Numbers: ACRO01
Study First Received: October 21, 2011
Last Updated: February 28, 2012
Health Authority: Brazil: Ethics Committee

Additional relevant MeSH terms:
Vitiligo
Hypopigmentation
Pigmentation Disorders
Skin Diseases

ClinicalTrials.gov processed this record on October 21, 2014